Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

BACKGROUND: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. Drug costs within these models are usually limited to the retail cost of both drugs at the time of model conception. However, the retail cost of the NPRx is expected to drop once generic versions...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clinicoecon Outcomes Res
Egile Nagusiak: Guertin, Jason R, Mitchell, Dominic, Ali, Farzad, LeLorier, Jacques
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4605233/
https://ncbi.nlm.nih.gov/pubmed/26504402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S90386
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak